Measures · D09 in 2026 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing
Medication Adherence for Hypertension (RAS antagonists)
Drug PlanMedication AdherenceSource: Prescription Drug Events
- What it measures
- The percentage of plan members with a prescription for a blood pressure medication who fill their prescription often enough to cover 80% or more of the time they are taking the medication. One of the most important ways people with high blood pressure can manage their health is by their taking medication. The plan, the doctor, and the member can work together to do this. (“Blood pressure medication” means an ACEI (angiotensin converting enzyme inhibitor), an ARB (angiotensin receptor blocker), or a direct renin inhibitor drug.)
- How it's calculated
- This measure is defined as the percentage of Medicare Part D beneficiaries, 18 years and older, who adhere to their prescribed drug therapy for renin angiotensin system (RAS) antagonists: ACEI, ARB, or direct renin inhibitor medications. The proportion of days covered (PDC) is the percentage of days in the measurement period “covered” by prescription claims for the same medication or another in its therapeutic category. The index prescription start date (IPSD) is the earliest date of service for the target medication during the measurement year. The treatment period begins on the IPSD and extends through whichever comes first: the last day of enrollment during the measurement year, death, or the end of the measurement year. The treatment period must be at least 91 days during the measurement year. Continuous enrollment (CE) is defined as being continuously enrolled in a Medicare Part D contract during the treatment period with no enrollment gaps allowed during the treatment period. This percentage is calculated as the number of continuously enrolled beneficiaries, 18 years and older, with a PDC of 80 percent or higher for RAS antagonist medications during the measurement period (numerator) divided by the number of continuously enrolled beneficiaries, 18 years and older, with at least two RAS antagonist medication fills on unique dates of service during the measurement period, and a treatment period that is at least 91 days during the measurement year (denominator). The Part D Medication Adherence measure is adapted from the Medication Adherence-Proportion of Days Covered measure that was developed and endorsed by the PQA. See the medication list for this measure. The Part D Medication Adherence rate is calculated using the NDC list maintained by the PQA. The complete NDC list, including diagnosis codes, is posted along with these technical notes.
- Data source
- Prescription Drug Event (PDE) data The data for this measure come from PDE data submitted to the CMS DDPS and accepted by the 2024 PDE submission deadline for annual Part D payment reconciliation with dates of service from January 1, 2024-December 31, 2024. If the PDE edit results in the PDE being rejected by DDPS, then the PDE is not used in the Patient Safety measure calculations. If the PDE edit is informational and therefore does not result in the PDE being rejected, then the PDE is used in the Patient Safety measure calculations. Reminder, CMS uses the term “final action” PDE to describe the most recently accepted original, adjustment, or deleted PDE record representing a single dispensing event. Original and adjustment final action PDEs submitted by the sponsor and accepted by DDPS prior to the 2024 PDE submission deadline are used to calculate this measure. PDE claims are limited to members who received at least two prescriptions on unique dates of service for RAS antagonist medication(s). PDE adjustments made post-reconciliation were not reflected in this measure. Additional data sources include the CME, the CWF, and the EDS. The data cutoff date for all the additional data sources listed below such as the CME, CWF, and EDS is determined by the same PDE submission deadline for the annual Part D payment reconciliation. • CME is used for enrollment information and to identify beneficiaries who elected to receive hospice care or with ESRD status (dialysis start and end dates within the measurement period). • CWF is used to identify exclusion diagnoses based on ICD-10-CM codes, inpatient • and SNF stays for PDPs and MA-PDs (if available). • EDS is used to identify exclusion diagnoses based on ICD-10-CM codes, and SNF/IP stays for MA-PD beneficiaries.
- Measurement period
- 01/01/2024 – 12/31/2024
- Better when
- Higher
- Weight
- 3 (Intermediate Outcome Measure)
- Star assignment
- Clustering
- Case-mix adjusted
- No
- In improvement measure
- Yes
- Used in CAI
- Yes
- Exclusions
Show
Contracts with 30 or fewer continuously enrolled beneficiaries (in the denominator). The following beneficiaries are also excluded from the denominator if at any time during the measurement period unless otherwise specified: • In hospice • ESRD diagnosis or dialysis coverage dates • One or more prescriptions for sacubitril/valsartan during the treatment period- Notes
- Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the PQA medication or NDC lists, are excluded from CMS analyses. The PDC calculation is adjusted for overlapping prescriptions for the same drug which is defined by active ingredient at the generic name level using the NDC list maintained by PQA. The calculation also adjusts for Part D beneficiaries’ stays in IP settings and stays in SNFs. The discharge date is included as an adjustment day for IP/SNF stays. Please see Attachment L: Medication Adherence Measure Calculations for more information about these calculation adjustments. When available, beneficiary death date from the CME is the end date of a beneficiary’s treatment period.
- Disaster policy
- Higher measure star (2025-2026) for contracts with 25% or more enrolled affected by 2024 disasters. Meaningful Measure Chronic Conditions Area:
From the 2026 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 84 | 85 | +1 |
| 3★ | MA-PD | 88 | 89 | +1 |
| 4★ | MA-PD | 90 | 91 | +1 |
| 5★ | MA-PD | 93 | 94 | +1 |
| 2★ | PDP | 87 | 88 | +1 |
| 3★ | PDP | 89 | 90 | +1 |
| 4★ | PDP | 90 | 91 | +1 |
| 5★ | PDP | 92 | 92 | 0 |
2026 star distribution
Not rated: Plan too new to be measured (93); Not enough data available (33); Plan not required to report measure (8)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 84 % | >= 84 % to < 88 % | >= 88 % to < 90 % | >= 90 % to < 93 % | >= 93 % |
| 2027 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2026 | MA-PD | < 84 % | >= 84 % to < 88 % | >= 88 % to < 91 % | >= 91 % to < 93 % | >= 93 % |
| 2026 | PDP | < 88 % | >= 88 % to < 90 % | >= 90 % to < 91 % | >= 91 % to < 93 % | >= 93 % |
| 2025 | MA-PD | < 83 % | >= 83 % to < 87 % | >= 87 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2025 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2024 | MA-PD | < 82 % | >= 82 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2024 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 91 % | >= 91 % to < 94 % | >= 94 % |
| 2023 | MA-PD | < 78 % | >= 78 % to < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2023 | PDP | < 86 % | >= 86 % to < 89 % | >= 89 % to < 91 % | >= 91 % to < 96 % | >= 96 % |
| 2022 | MA-PD | < 74 % | >= 74 % to < 82 % | >= 82 % to < 87 % | >= 87 % to < 90 % | >= 90 % |
| 2022 | PDP | < 85 % | >= 85 % to < 88 % | >= 88 % to < 89 % | >= 89 % to < 91 % | >= 91 % |
| 2021 | MA-PD | < 80 % | >= 80 % to < 84 % | >= 84 % to < 87 % | >= 87 % to < 89 % | >= 89 % |
| 2021 | PDP | < 84 % | >= 84 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 90 % | >= 90 % |
| 2020 | MA-PD | < 80% | ? 80% to < 83% | ? 83% to < 86% | ? 86% to < 88% | ? 88% |
| 2020 | PDP | < 83% | ? 83% to < 85% | ? 85% to < 88% | ? 88% to < 90% | ? 90% |
| 2019 | MA-PD | < 79% | ? 79% to < 83% | ? 83% to < 86% | ? 86% to < 88% | ? 88% |
| 2019 | PDP | < 84% | ? 84% to < 86% | ? 86% to < 87% | ? 87% to < 89% | ? 89% |
| 2018 | MA-PD | < 74% | ? 74% to < 78% | ? 78% to < 82% | ? 82% to < 85% | ? 85% |
| 2018 | PDP | < 78% | ? 78% to < 83% | ? 83% to < 86% | ? 86% to < 89% | ? 89% |
| 2017 | MA-PD | < 71% | ? 71% to < 75% | ? 75% to < 79% | ? 79% to < 83% | ? 83% |
| 2017 | PDP | < 77% | ? 77% to < 80% | ? 80% to < 83% | ? 83% to < 85% | ? 85% |
| 2016 | MA-PD | < 58% | ? 58% to < 73% | ? 73% to < 77% | ? 77% to < 81% | ? 81% |
| 2016 | PDP | < 76% | ? 76% to < 78% | ? 78% to < 82% | ? 82% to < 85% | ? 85% |
| 2015 | MA-PD | < 72% | ? 72% to < 76% | ? 76% to < 81% | ? 81% to < 85% | ? 85% |
| 2015 | PDP | < 72% | ? 72% to < 76% | ? 76% to < 81% | ? 81% to < 84% | ? 84% |
Lowest-scoring contracts, 2026
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| S5795 Arkansas Blue Medicare | USAble Mutual Insurance Company | 19,195 | 86 | 1 | 0 | 5 | 0% |
| S5921 UnitedHealthcare | UnitedHealth Group, Inc. | 2,326,418 | 86 | 1 | −1 | 5 | 0% |
| H3467 ProCare Advantage | First Sacramento Capital Funding LLC | 1,010 | 66 | 1 | 0 | 25 | 0% |
| H6891 American Health Advantage of Texas | Mitchell Family Office | 421 | 73 | 1 | 0 | 18 | 0% |
| H6832 Align Senior Care | Curana Health Holdings, LLC | 1,535 | 74 | 1 | 0 | 17 | 0% |
| H4054 Provider Partners Health Plans | Rifkin Managed Care Holding, LLC | 2,485 | 75 | 1 | 0 | 16 | 1% |
| H3800 Provider Partners Health Plans | Rifkin Managed Care Holding, LLC | 1,079 | 76 | 1 | 0 | 15 | 1% |
| H6248 Community Health Group | Community Health Group | 646 | 77 | 1 | — | 14 | 1% |
| H9066 Nascentia Health Plus | VISITING NURSE ASSOCIATION OF CENTRAL NEW YORK | 663 | 79 | 1 | −1 | 12 | 1% |
| H3407 El Paso Health Medicare Advantage | El Paso County Hospital District | 2,178 | 79 | 1 | 0 | 12 | 1% |
| H8854 CareFirst BlueCross BlueShield Advantage DualPrime | CareFirst, Inc. | 8,599 | 80 | 1 | 0 | 11 | 1% |
| H3551 eternalHealth | Eternal Health of Delaware, Inc. | 2,467 | 81 | 1 | — | 10 | 2% |
| H9909 American Health Advantage of MS | Mitchell Family Office | 774 | 81 | 1 | −1 | 10 | 2% |
| H8492 American Health Advantage of Louisiana | Mitchell Family Office | 729 | 81 | 1 | 0 | 10 | 2% |
| H3727 Communicare Advantage | SNP Holdings, LLC | 2,314 | 82 | 1 | 0 | 9 | 2% |
| H9917 Align Senior Care | Curana Health Holdings, LLC | 408 | 82 | 1 | 0 | 9 | 2% |
| H4704 Anthem Blue Cross Life and Health Insurance Company | Elevance Health, Inc. | 7,648 | 82 | 1 | — | 9 | 2% |
| H0034 Hamaspik, Inc. | Hamaspik of Rockland County, Inc. | 2,714 | 83 | 1 | −1 | 8 | 3% |
| H5580 Mercy Care Advantage | Mercy Care | 10,965 | 83 | 1 | −1 | 8 | 3% |
| H3814 ATRIO Health Plans | ATRIO Health Plans | 1,997 | 83 | 1 | 0 | 8 | 3% |
| H6322 McLaren Medicare | McLaren Health Care Corporation | 2,400 | 84 | 2 | −1 | 7 | 3% |
| H8894 IEHP DualChoice | INLAND EMPIRE HEALTH PLAN | 38,360 | 84 | 2 | 0 | 7 | 3% |
| H2247 UnitedHealthcare | UnitedHealth Group, Inc. | 39,518 | 84 | 2 | 0 | 7 | 3% |
| H1347 Patrius Health | BlueCross BlueShield of Alabama | 4,544 | 84 | 2 | 0 | 7 | 3% |
| R7220 Humana | Humana Inc. | 2,904 | 85 | 2 | −1 | 6 | 4% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2025 – 12/31/2025 | 3 | Prescription Drug Events |
| 2026 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2024 – 12/31/2024 | 3 | Prescription Drug Events |
| 2025 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2023 – 12/31/2023 | 3 | Prescription Drug Events |
| 2024 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2022 – 12/31/2022 | 3 | Prescription Drug Events |
| 2023 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2021 – 12/31/2021 | 3 | Prescription Drug Events |
| 2022 | D09 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2020 – 12/31/2020 | 3 | Prescription Drug Events |
| 2021 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2019 – 12/31/2019 | 3 | Prescription Drug Events |
| 2020 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2018 – 12/31/2018 | 3 | Prescription Drug Events |
| 2019 | D11 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2017 – 12/31/2017 | 3 | Prescription Drug Events |
| 2018 | D12 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2016 – 12/31/2016 | 3 | Prescription Drug Events |
| 2017 | D13 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2015 - 12/31/2015 | 3 | Prescription Drug Events |
| 2016 | D13 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2014 - 12/31/2014 | 3 | Prescription Drug Events |
| 2015 | D12 | Medication Adherence for Hypertension (RAS antagonists) | 01/01/2013 - 12/31/2013 | 3 | Prescription Drug Events |